PAVmed Q3 net loss $26.2M ($0.29/sh); EsoGuard volumes up 28% qoq to 1,088

PAVmed Inc.

2023-Q3 EPS reported -$0.78 revenue$189,000

GAAP net loss of $26.2M ($0.29 per share); non-GAAP adjusted loss of $13.8M ($0.15 per share).
EsoGuard test volumes of 1,088 in Q3 2022, up 28% sequentially and 436% YoY.
Cash and equivalents $56.8M at Sep 30, 2022, down from $77.3M at Dec 31, 2021.
Issued $11.25M face value Senior Secured Convertible Note in Sep 2022; proceeds $10.2M.
Veris Cancer Care Platform on track for commercial launch by end 2022; Lucid sales team targeting 58 professionals early 2023.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PAVmed Inc. reported the three months ended September 30, 2022 results: revenue $0.1 million, net income approximately $26.2 million, EPS $(0.29) per common share.

Period: the three months ended September 30, 2022
Revenue: $0.1 million
Net income: approximately $26.2 million
EPS: $(0.29) per common share
Result: reported results

Exact text from the filing

For the three months ended September 30, 2022, EsoGuard related revenues were $0.1 million. Operating expenses were approximately $23.4 million, which include stock-based compensation expenses of $4.8 million. GAAP net loss attributable to common stockholders was approximately $26.2 million, or $(0.29) per common share.

View on SEC.gov

Browse all earnings releases →

PAVmed Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-032536

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.